January 5, 2024
June 2, 2023
selectION awaits efficacy data from trial of Kv1.3 ion channel blocker in atopic dermatitis
May 30, 2023
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
November 29, 2022
Immusoft Receives $4M In Funding From The California Institute For Regenerative Medicine (CIRM)
October 17, 2022
Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
September 12, 2022
selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients
September 1, 2022
Immusoft Announces FDA Clearance Of IND Application For ISP-001 For MPS I, The First Engineered B Cell Therapy To Enter Into Clinical Trials
May 9, 2022
selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development
October 19, 2021
Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit
October 13, 2021